BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $125.48 Million Holdings in Eli Lilly and Company (NYSE:LLY)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 15.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 141,635 shares of the company's stock after selling 25,332 shares during the quarter. Eli Lilly and Company makes up approximately 0.8% of BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings, making the stock its 25th largest position. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in Eli Lilly and Company were worth $125,480,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Peterson Financial Group Inc. bought a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $27,000. MidAtlantic Capital Management Inc. bought a new position in Eli Lilly and Company during the 3rd quarter worth $30,000. Lynx Investment Advisory bought a new position in Eli Lilly and Company during the 2nd quarter worth $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company in the second quarter worth $36,000. Finally, Cedar Mountain Advisors LLC lifted its stake in Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company's stock valued at $41,000 after buying an additional 16 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.9 %

Shares of LLY traded up $7.16 during trading hours on Friday, reaching $795.35. The company's stock had a trading volume of 2,206,918 shares, compared to its average volume of 3,213,011. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market cap of $755.04 billion, a price-to-earnings ratio of 85.98, a P/E/G ratio of 2.99 and a beta of 0.43. The company has a 50 day moving average of $851.90 and a two-hundred day moving average of $869.52. Eli Lilly and Company has a 1-year low of $561.65 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion for the quarter, compared to analysts' expectations of $12.09 billion. During the same quarter in the prior year, the business posted $0.10 earnings per share. Eli Lilly and Company's revenue was up 20.4% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 13.2 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.65%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company's payout ratio is presently 56.22%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on LLY shares. Guggenheim lifted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a "buy" rating in a report on Friday, August 16th. Wolfe Research started coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 target price on the stock. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a "buy" rating in a research report on Wednesday, August 14th. Morgan Stanley reissued an "overweight" rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Finally, Bank of America cut their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a "buy" rating on the stock in a research note on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,007.94.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.